bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
Authors: Jo Hitomi , Yagishita Shigehiro , Hayashi Yoshiharu , Ryu Shoraku , Suzuki Mikiko , Kohsaka Shinji , Ueno Toshihide , Matsumoto Yuji , Horinouchi Hidehito , Ohe Yuichiro , Watanabe Shun-ichi , Motoi Noriko , Yatabe Yasushi , Mano Hiroyuki , Takahashi Kazuhisa , Hamada Akinobu
Published: April 2023

Supplementary Table 1
(A) MRM transitions of each compound(B) LC condition(C) MS/MS Parameters were optimized for each compound(D) MALDI-MS analytical conditions of the testing drugs
Supplementary Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
Authors: Ishi Yukitomo , Zhang Yongzhan , Zhang Ali , Sasaki Takahiro , Piunti Andrea , Suri Amreena , Watanabe Jun , Abe Kouki , He Xingyao , Katagi Hiroaki , Bhalla Pankaj , Natsumeda Manabu , Zou Lihua , Shilatifard Ali , Hashizume Rintaro
Published: April 2023

Supplementary Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Authors: Bahcall Magda , Paweletz Cloud P. , Kuang Yanan , Taus Luke J. , Sim Taebo , Kim Nam Doo , Dholakia Kshiti H. , Lau Christie J. , Gokhale Prafulla C. , Chopade Pratik R. , Hong Fangxin , Wei Zihan , Köhler Jens , Kirschmeier Paul T. , Guo Jiannan , Guo Sujuan , Wang Stephen , Jänne Pasi A.
Published: April 2023

Supplementary Figures S1-3; Supplementary Tables S1-3
Supplementary Figure S5 from Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases
Authors: Fox Gregory C. , Su Xinming , Davis Jennifer L. , Xu Yalin , Kwakwa Kristin A. , Ross Michael H. , Fontana Francesca , Xiang Jingyu , Esser Alison K. , Cordell Elizabeth , Pagliai Kristen , Dang Ha X. , Sivapackiam Jothilingam , Stewart Sheila A. , Maher Christopher A. , Bakewell Suzanne J. , Fitzpatrick James A.J. , Sharma Vijay , Achilefu Samuel , Veis Deborah J. , Lanza Gregory M. , Weilbaecher Katherine N.
Published: April 2023

4T1 oxygen consumption rate on tissue culture-treated and poly-L-lysine-coated plates.
Supplementary Data from EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1
Authors: Weadick Brenna , Nayak Debasis , Persaud Avinash K. , Hung Sau Wai , Raj Radhika , Campbell Moray J. , Chen Wei , Li Junan , Williams Terence M. , Govindarajan Rajgopal
Published: April 2023

I. Supplemental Materials and Methods (p. 2-7) II. Supplemental Figures and Table (p. 8-31) III. Supplemental Files Legend (p. 32)
Supplemental File 3 from EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1
Authors: Weadick Brenna , Nayak Debasis , Persaud Avinash K. , Hung Sau Wai , Raj Radhika , Campbell Moray J. , Chen Wei , Li Junan , Williams Terence M. , Govindarajan Rajgopal
Published: April 2023

Video 3. N+/E- cells 3D reconstruction animation shows localization of ENT1 (red) and DAPI (blue)
Video S2A from Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers
Authors: Duranti Claudia , Iorio Jessica , Lottini Tiziano , Lastraioli Elena , Crescioli Silvia , Bagni Giacomo , Lulli Matteo , Capitani Chiara , Bouazzi Rayhana , Stefanini Matteo , Carraresi Laura , Iamele Luisa , De Jonge Hugo , Arcangeli Annarosa
Published: April 2023

Non Linear Contrast Mode imaging of mouse kidneys 3 hours after the injection of 8mg/kg of scDb
Supplementary Fig. 5 from Radiosensitizing Pancreatic Cancer via Effective Autophagy Inhibition
Authors: Yazal Taha , Bailleul Justine , Ruan Yangjingyi , Sung David , Chu Fang-I , Palomera Daisy , Dao Amy , Sehgal Anahita , Gurunathan Vibha , Aryan Laila , Eghbali Mansoureh , Vlashi Erina
Published: April 2023

Supplementary Figure S5 shows representative images for sphere forming capacity assay.
Supplementary Fig. 4 from Radiosensitizing Pancreatic Cancer via Effective Autophagy Inhibition
Authors: Yazal Taha , Bailleul Justine , Ruan Yangjingyi , Sung David , Chu Fang-I , Palomera Daisy , Dao Amy , Sehgal Anahita , Gurunathan Vibha , Aryan Laila , Eghbali Mansoureh , Vlashi Erina
Published: April 2023

Supplementary Figure S4 shows clonogenic assays, statistical analysis and representative images.
Supplementary Fig. 2 from Radiosensitizing Pancreatic Cancer via Effective Autophagy Inhibition
Authors: Yazal Taha , Bailleul Justine , Ruan Yangjingyi , Sung David , Chu Fang-I , Palomera Daisy , Dao Amy , Sehgal Anahita , Gurunathan Vibha , Aryan Laila , Eghbali Mansoureh , Vlashi Erina
Published: April 2023

Supplementary Figure S2 shows flow cytometry histograms for ALDH activity.
Video S1C from Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers
Authors: Duranti Claudia , Iorio Jessica , Lottini Tiziano , Lastraioli Elena , Crescioli Silvia , Bagni Giacomo , Lulli Matteo , Capitani Chiara , Bouazzi Rayhana , Stefanini Matteo , Carraresi Laura , Iamele Luisa , De Jonge Hugo , Arcangeli Annarosa
Published: April 2023

Non Linear Contrast Mode imaging of mouse kidneys 3 hours after the injection of saline solution (CTRL)
Supplementary Tables from A Benzenesulfonamide-Based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian Cancer
Authors: Bi Fangfang , Jiang Ziyan , Park Wonmin , Hartwich Tobias M.P. , Ge Zhiping , Chong Kay Y. , Yang Kevin , Morrison Madeline J. , Kim Dongin , Kim Jaeyeon , Zhang Wen , Kril Liliia M. , Watt David S. , Liu Chunming , Yang-Hartwich Yang
Published: April 2023

Supplementary Tables S1-S4
Video S1B from Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers
Authors: Duranti Claudia , Iorio Jessica , Lottini Tiziano , Lastraioli Elena , Crescioli Silvia , Bagni Giacomo , Lulli Matteo , Capitani Chiara , Bouazzi Rayhana , Stefanini Matteo , Carraresi Laura , Iamele Luisa , De Jonge Hugo , Arcangeli Annarosa
Published: April 2023

Non Linear Contrast Mode imaging of mouse kidneys 3 hours after the injection of saline solution (CTRL)
Supplementary Data from F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd
Authors: Morris Joel , Wishka Donn G. , Lopez Omar D. , Rudchenko Vladimir , Huang Guangfei , Hoffman Sierra N. , Borgel Suzanne , Georgius Kyle , Carter John , Stotler Howard , Kunkel Mark W. , Collins Jerry M. , Hollingshead Melinda G. , Teicher Beverly A.
Published: April 2023

Supplementary material
Supplementary Table from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer
Authors: Huang Kuan-Chun , Chandra Dinesh , McGrath Shannon , Dixit Vaishali , Zhang Chi , Wu Jiayi , Tendyke Karen , Yao Huilan , Hukkanen Renee , Taylor Noel , Verbel David , Kim Dae-Shik , Endo Atsushi , Noland Thomas A. , Chen Yu , Matijevic Mark , Wang John , Hutz Janna , Sarwar Nadeem , Fang Francis G. , Bao Xingfeng
Published: April 2023

Supplementary Table from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer
Supplementary Figures references from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Supplementary references
Figure S8 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Drug diffusion profiles for cisplatin and paclitaxel
Figure S3 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Tumor tissue autofluorescence
Figure S2 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Tumor sample viability
Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Authors: Diamond Jennifer R. , Pitts Todd M. , Ungermannova Dana , Nasveschuk Christopher G. , Zhang Gan , Phillips Andrew J. , Bagby Stacey M. , Pafford Jessica , Yacob Betelehem W. , Newton Timothy P. , Tentler John J. , Gittleman Brian , Hartman Sarah J. , DeMattei John A. , Winkler James D. , Wendt Michael K. , Schiemann William P. , Eckhardt S. Gail , Liu Xuedong , Piscopio Anthony D.
Published: April 2023

Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Figure S11 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

COMPUSYN analyses for paclitaxel and vincristine
Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Authors: Diamond Jennifer R. , Pitts Todd M. , Ungermannova Dana , Nasveschuk Christopher G. , Zhang Gan , Phillips Andrew J. , Bagby Stacey M. , Pafford Jessica , Yacob Betelehem W. , Newton Timothy P. , Tentler John J. , Gittleman Brian , Hartman Sarah J. , DeMattei John A. , Winkler James D. , Wendt Michael K. , Schiemann William P. , Eckhardt S. Gail , Liu Xuedong , Piscopio Anthony D.
Published: April 2023

Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Figure S10 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Drug diffusion profiles for paclitaxel and vincristine
Supplementary Figure from Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Authors: Adashek Jacob J. , Menta Arjun K. , Reddy Neha K. , Desai Aakash P. , Roszik Jason , Subbiah Vivek
Published: April 2023

Supplementary Figure from Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Supplementary Figure S8 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

Combination effect of rituximab plus doxorubicin or prednisolone in obinutuzumab resistant clones.
Supplementary Figure S7 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

Confirmation of the combination effects in cells refractory to obinutuzumab-induced direct cell death.
Supplementary Figure S6 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

The in vivo antitumor effect of obinutuzumab in SU-DHL-4 cells transplanted mouse xenograft model.
Supplementary Figure S5 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

Combination effect of obinutuzumab plus prednisolone on induction of cell death and on G0/G1 arrest in clones 7C2 and 1D6.
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Figure 2. Gene Ontology (GO) enrichment analysis indicates OCI-C5x cells are more vulnerable to epigenetic interventions than OCI-P5x cells
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Figure 4. Dose-response curves of BET inhibitors JQ1 and CPI203 in OCCC cells.
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
Authors: Shigeta Shogo , Lui Goldie Y.L. , Shaw Reid , Moser Russell , Gurley Kay E. , Durenberger Grace , Rosati Rachele , Diaz Robert L. , Ince Tan A. , Swisher Elizabeth M. , Grandori Carla , Kemp Christopher J.
Published: April 2023

Supplementary Table 5. The results of RNA-Seq.
Supplementary Figures from Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer
Authors: Cruz-Collazo Ailed , Ruiz-Calderon Jean F. , Picon Hector , Borrero-Garcia Luis D. , Lopez Irmaris , Castillo-Pichardo Linette , del Mar Maldonado Maria , Duconge Jorge , Medina Julia I. , Bayro Marvin J. , Hernández-O'Farrill Eliud , Vlaar Cornelis P. , Dharmawardhane Suranganie
Published: April 2023

Supplementary Figures
Supplementary Data from ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib
Authors: Li Wenlong , Sparidans Rolf W. , Martins Margarida L.F. , El-Lari Mujtaba , Lebre Maria C. , van Tellingen Olaf , Beijnen Jos H. , Schinkel Alfred H.
Published: April 2023

Supplementary Figures 1-7 and legends, and Supplementary Table 1, 2
Supplementary Table S5 from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Authors: Gartrell Jessica , Mellado-Largarde Marcia , Clay Michael R. , Bahrami Armita , Sahr Natasha A. , Sykes April , Blankenship Kaley , Hoffmann Lauren , Xie Jia , Cho Hyekyung P. , Twarog Nathaniel , Connelly Michele , Yan Koon-Kiu , Yu Jiyang , Porter Shaina N. , Pruett-Miller Shondra M. , Neale Geoffrey , Tinkle Christopher L. , Federico Sara M. , Stewart Elizabeth A. , Shelat Anang A.
Published: April 2023

Supplementary Table S5
Supplementary Table S4 from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Authors: Gartrell Jessica , Mellado-Largarde Marcia , Clay Michael R. , Bahrami Armita , Sahr Natasha A. , Sykes April , Blankenship Kaley , Hoffmann Lauren , Xie Jia , Cho Hyekyung P. , Twarog Nathaniel , Connelly Michele , Yan Koon-Kiu , Yu Jiyang , Porter Shaina N. , Pruett-Miller Shondra M. , Neale Geoffrey , Tinkle Christopher L. , Federico Sara M. , Stewart Elizabeth A. , Shelat Anang A.
Published: April 2023

Supplementary Table S4
Supplementary Table S2 from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Authors: Gartrell Jessica , Mellado-Largarde Marcia , Clay Michael R. , Bahrami Armita , Sahr Natasha A. , Sykes April , Blankenship Kaley , Hoffmann Lauren , Xie Jia , Cho Hyekyung P. , Twarog Nathaniel , Connelly Michele , Yan Koon-Kiu , Yu Jiyang , Porter Shaina N. , Pruett-Miller Shondra M. , Neale Geoffrey , Tinkle Christopher L. , Federico Sara M. , Stewart Elizabeth A. , Shelat Anang A.
Published: April 2023

Supplementary Table S2
Supplementary Data from SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Authors: Gartrell Jessica , Mellado-Largarde Marcia , Clay Michael R. , Bahrami Armita , Sahr Natasha A. , Sykes April , Blankenship Kaley , Hoffmann Lauren , Xie Jia , Cho Hyekyung P. , Twarog Nathaniel , Connelly Michele , Yan Koon-Kiu , Yu Jiyang , Porter Shaina N. , Pruett-Miller Shondra M. , Neale Geoffrey , Tinkle Christopher L. , Federico Sara M. , Stewart Elizabeth A. , Shelat Anang A.
Published: April 2023

Detailed methods, description of supplemental tables, and supplemental figures.
Supplementary Table from Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
Authors: Yamamoto Tomomi M. , Webb Patricia G. , Davis Dana M. , Baumgartner Heidi K. , Woodruff Elizabeth R. , Guntupalli Saketh R. , Neville Margaret , Behbakht Kian , Bitler Benjamin G.
Published: April 2023

Supplementary Table from Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
Supplementary Fig S6 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S6. HeSPs strongly reduce the levels of heme transporters without affecting iron metabolism in subcutaneous NSCLC tumor xenografts. A, Representative IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of SLC48A1 in control and HeSP-treated tumors. B, Representative IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of SLC46A1 in control and HeSP-treated tumors. C, Representative IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of FLVCR2 in control and HeSP-treated tumors. D, Representative IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of ferroportin 1, SLC40A1, in control and HeSP-treated tumors. E, Representative IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of transferrin receptor TFRC in control and HeSP-treated tumors. Shown IHC figures are montages or 10X images of control and HeSP-treated tumor tissue sections stained with DAPI or antibodies against the indicated protein. The white rectangles in DAPI images denote the regions shown in 10X images. Liver is shown as a positive control for the detection of all proteins shown. Scale bar: montage, 1 mm; 10X, 200 Î¼m. F, Representative 40X IHC images of H1299 NSCLC tumor tissue sections showing the colocalization of FLVCR2, SLC46A1, TFRC, and SLC40A1 with membrane marker PMCA1. Scale bar, 20 Âµm. G, Iron stain did not detect noticeable difference between control and treated tumor tissues. (Left) Shown are montages, 10X, and 40X images of control and HeSP-treated tumor tissue sections stained with iron stain. Liver is shown as a positive control for iron stain. The black rectangles in montages, 10X images are the regions shown in 10X and 40X images, respectively. Scale bar: montage, 1 mm; 10X, 200 Âµm; 40X, 50 Âµm. (Right) The levels of iron in tumor lysates from control mice and mice treated with HeSPs. Liver lysates were used as a positive control while BSA solution was used as a negative control. Protein and iron levels were quantified. Data were plotted as mean {plus minus} SEM. **, P < 0.01; ***, P < 0.005.
Supplementary Data from A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
Authors: Zimmermann Astrid , Zenke Frank T. , Chiu Li-Ya , Dahmen Heike , Pehl Ulrich , Fuchss Thomas , Grombacher Thomas , Blume Beatrix , Vassilev Lyubomir T. , Blaukat Andree
Published: April 2023

Supplementary Data from A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
Supplementary Data from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
Authors: Lee Supum , Cavaliere Alessandra , Gallezot Jean-Dominique , Keler Tibor , Michelhaugh Sharon K. , Belitzky Erika , Liu Michael , Mulnix Tim , Maher Stephen E. , Bothwell Alfred L.M. , Li Fangyong , Phadke Manali , Mittal Sandeep , Marquez-Nostra Bernadette
Published: April 2023

Supplementary Data from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
Supplementary Table 4 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Gene expression differences between AR-High versus AR-Low MDA-MB-453 cells
Supplementary Table 3 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Genes correlated with AR expression in MDA-MB-453 cells
Supplementary Table 1 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Gene expression changes following DHT treatment in HCI-009 PDXs
Supplementary Figure 1 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Sevi method of action. (A) Schematic of the seviteronel (Sevi) mechanism of action.
Supplementary Data from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
Authors: Martinez-Velez Naiara , Laspidea Virginia , Zalacain Marta , Labiano Sara , García-Moure Marc , Puigdelloses Montse , Marrodan Lucía , Gonzalez-Huarriz Marisol , Herrador Guillermo , de la Nava Daniel , Ausejo-Mauleon Iker , Fueyo Juan , Gomez-Manzano Candelaria , Patiño-García Ana , Alonso Marta M.
Published: April 2023

Supplementary Data from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
Supplementary Figure S1-S6 from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow
Authors: Zhang Chao , Xu Xiaoxuan , Trotter Timothy N. , Gowda Pramod S. , Lu Yun , Suto Mark J. , Javed Amjad , Murphy-Ullrich Joanne E. , Li Juan , Yang Yang
Published: April 2023

Supplementary Figure S1-S6
Supplementary Figure S1 shows tumor burden in the mice before BTZ treatment started (S1A), MM cell growth and apoptosis after co-cultured with BMS or pre-OBs of OB-Runx2-/- or OB-Runx2+/+ mice (S1B-F), and the proportion of PMN-MDSCs and M-MDSCs in the BM of Runx2-/- or OB-Runx2+/+ mice after 4-week treatment with BTZ (S1G-H).Supplementary Figure S2 shows tumor burden in the mice before SRI31277 and BTZ treatment (S2A) and the proportion of PMN-MDSCs and M-MDSCs in the BM of Runx2-/- or OB-Runx2+/+ mice after 4-week treatment with SRI31277 and BTZ (S2B-C).Supplementary Figure S3 shows tumor burden in the mice before 5-Fu and BTZ treatment.Supplementary Figure S4 shows the impact of GEM treatment on BTZ resistance of MM cells in OB-Runx2-/- mice.Supplementary Figure S5 shows the proportion of PMN-MDSCs and M-MDSCs in the BM of Runx2-/- or OB-Runx2+/+ mice after 4-week treatment with 5-Fu and BTZ.Supplementary Figure S6 shows the impact of GEM and BTZ treatment on MDSCs and CD8 T cells.
Supplementary Methods from Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid–coated Layer-by-Layer Nanoparticles
Authors: Tošić Isidora , Heppler Lisa N. , Egusquiaguirre Susana P. , Boehnke Natalie , Correa Santiago , Costa Daniel F. , Moore Elizabeth A. Grossman , Pal Sharmistha , Richardson Douglas S. , Ivanov Alexander R. , Haas-Kogan Daphne A. , Nomura Daniel K. , Hammond Paula T. , Frank David A.
Published: April 2023

Supplementary Methods
Supplementary Data from Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
Authors: Lee Wen-Hsin Sandy , Ye Zhiyong , Cheung Alice M.S. , Goh Y.P. Sharon , Oh Hsueh Ling Janice , Rajarethinam Ravisankar , Yeo Siok Ping , Soh Mun Kuen , Chan Esther Hian Li , Tan Lip Kun , Tan Soo-Yong , Chuah Charles , Chng Wee Joo , Connolly John E. , Wang Cheng-I
Published: April 2023

Supplementary figures and methods.
Supplementary video S2 from Enhancing Proteotoxic Stress in Leiomyosarcoma Cells Triggers Mitochondrial Dysfunctions, Cell Death, and Antitumor Activity in vivo
Authors: Iuliano Luca , Drioli Sara , Pignochino Ymera , Cafiero Claudia Maria , Minisini Martina , D'Este Francesca , Picco Raffaella , Dalla Emiliano , Giordano Giorgia , Grignani Giovanni , Di Giorgio Eros , Benedetti Fabio , Felluga Fulvia , Brancolini Claudio
Published: April 2023

Mitochondrial dynamic in 2c treated SK-UT-1 cells
Supplementary figs from C/EBPβ/AEP Signaling Regulates the Oxidative Stress in Malignant Cancers, Stimulating the Metastasis
Authors: Lei Kecheng , Kang Seong Su , Ahn Eun Hee , Chen Chun , Liao Jianming , Liu Xia , Li Hua , Edgington-Mitchell Laura E. , Jin Lingjing , Ye Keqiang
Published: April 2023

Supplementary figs
Table S3 from Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody–Drug Conjugates in Pancreatic Cancer
Authors: Tsujii Shigehiro , Serada Satoshi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Nomura Taisei , Murakami Ichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Supplementary Table S3
Supplementary Methods and Figures from Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody–Drug Conjugates in Pancreatic Cancer
Authors: Tsujii Shigehiro , Serada Satoshi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Nomura Taisei , Murakami Ichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Supplementary Methods and Supplementary Fig. S1-S4
Figure S3 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure S3. Targeting DNMTs affects AR signaling.
Supplementary Data from Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Authors: Yurkovetskiy Aleksandr V. , Bodyak Natalya D. , Yin Mao , Thomas Joshua D. , Clardy Susan M. , Conlon Patrick R. , Stevenson Cheri A. , Uttard Alex , Qin LiuLiang , Gumerov Dmitry R. , Ter-Ovanesyan Elena , Bu Charlie , Johnson Alex J. , Gurijala Venu R. , McGillicuddy Dennis , DeVit Michael J. , Poling Laura L. , Protopopova Marina , Xu Ling , Zhang Qingxiu , Park Peter U. , Bergstrom Donald A. , Lowinger Timothy B.
Published: April 2023

Supplementary methods, data and Figures
Supplementary Material from The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
Authors: Briere David M. , Li Shuai , Calinisan Andrew , Sudhakar Niranjan , Aranda Ruth , Hargis Lauren , Peng David H. , Deng Jiehui , Engstrom Lars D. , Hallin Jill , Gatto Sole , Fernandez-Banet Julio , Pavlicek Adam , Wong Kwok-Kin , Christensen James G. , Olson Peter
Published: April 2023

Supplementary Material
Supplementary Table from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Authors: Spiliopoulou Pavlina , Spear Sarah , Mirza Hasan , Garner Ian , McGarry Lynn , Grundland-Freile Fabio , Cheng Zhao , Ennis Darren P. , Iyer Nayana , McNamara Sophie , Natoli Marina , Mason Susan , Blyth Karen , Adams Peter D. , Roxburgh Patricia , Fuchter Matthew J. , Brown Bob , McNeish Iain A.
Published: April 2023

Supplementary Table from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Supplementary Data from Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells
Authors: Yin Liyuan , Zhang Yi , Yin Lijuan , Ou Yan , Lewis Michael S. , Wang Ruoxiang , Zhau Haiyen E. , Zhou Qinghua , Chung Leland W.K.
Published: April 2023

This file contains Supplementary Tables S1 and S2, and Figures S1 - S6.
Supplementary Data from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Authors: Wang Yifei , Tian Xiangjun , Zhang Wendong , Zhang Zhongting , Lazcano Rossana , Hingorani Pooja , Roth Michael E. , Gill Jonathan D. , Harrison Douglas J. , Xu Zhaohui , Jusu Sylvester , Kannan Sankaranarayanan , Wang Jing , Lazar Alexander J. , Earley Eric J. , Erickson Stephen W. , Gelb Tara , Huxley Philip , Lahdenranta Johanna , Mudd Gemma , Kurmasheva Raushan T. , Houghton Peter J. , Smith Malcolm A. , Kolb Edward A. , Gorlick Richard
Published: April 2023

Supplementary Data from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Supplementary Data from A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer
Authors: Xu Dongbo , Cao Qiang , Wang Li , Wang Jianmin , Xu Bo , Attwood Kristopher , Wei Lei , Wu Yue , Smith Gary J. , Katsuta Eriko , Takabe Kazuaki , Chatta Gurkamal , Guru Khurshid A. , Goodrich David W. , Li Qiang J.
Published: April 2023

Supplementary Data from A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer
Figure S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Authors: Dong Yiyu , Gong Yongxing , Kuo Fengshen , Makarov Vladimir , Reznik Ed , Nanjangud Gouri J. , Aras Omer , Zhao Huiyong , Qu Rui , Fagin James A. , Sherman Eric J. , Xu Bin , Ghossein Ronald , Chan Timothy A. , Ganly Ian
Published: April 2023

Somatic genomic mutations in XTC.UC1 and HCC. Significantly mutated genes, as determined by the MutSig algorithm are shown. Left: overall count for each gene. Right: gene list.
Supplementary Figure 4 from Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress
Authors: Grayson Korie A. , Hope Jacob M. , Wang Wenjun , Reinhart-King Cynthia A. , King Michael R.
Published: April 2023

Supplementary Figure 4
Table S4 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Authors: Jiménez-Alcázar Miguel , Curiel-García Álvaro , Nogales Paula , Perales-Patón Javier , Schuhmacher Alberto J. , Galán-Ganga Marcos , Zhu Lucía , Lowe Scott W. , Al-Shahrour Fátima , Squatrito Massimo
Published: April 2023

Screening results U251 Val-083
Table S3 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Authors: Jiménez-Alcázar Miguel , Curiel-García Álvaro , Nogales Paula , Perales-Patón Javier , Schuhmacher Alberto J. , Galán-Ganga Marcos , Zhu Lucía , Lowe Scott W. , Al-Shahrour Fátima , Squatrito Massimo
Published: April 2023

Screening results T98G TMZ
Table S2 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Authors: Jiménez-Alcázar Miguel , Curiel-García Álvaro , Nogales Paula , Perales-Patón Javier , Schuhmacher Alberto J. , Galán-Ganga Marcos , Zhu Lucía , Lowe Scott W. , Al-Shahrour Fátima , Squatrito Massimo
Published: April 2023

Screening results U251 TMZ
Figure S4 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Changes in BRAF and ERK expression (Log normalized values) in individual dogs during vemurafenib treatment.
Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Canine InvUC, RNA-seq analyses.
Supplementary Figure from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
Authors: Hollmén Maija , Maksimow Mikael , Rannikko Jenna H. , Karvonen Matti K. , Vainio Marita , Jalkanen Sirpa , Jalkanen Markku , Mandelin Jami
Published: April 2023

Supplementary Figure from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
Figure S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Squamous papillomas (A, B), and squamous cell carcinoma (C) that developed in one of the dogs during vemurafenib treatment.
Supplementary Figures from Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer
Authors: Hampton James D. , Peterson Erica J. , Katner Samantha J. , Turner Tia H. , Alzubi Mohammad A. , Harrell J. Chuck , Dozmorov Mikhail G. , Turner Joseph B. McGee , Gigliotti Pam J. , Kraskauskiene Vita , Shende Mayuri , Idowu Michael O. , Puchalapalli Madhavi , Hu Bin , Litovchick Larisa , Katsuta Eriko , Takabe Kazuaki , Farrell Nicholas P. , Koblinski Jennifer E.
Published: April 2023

Supplemental Figures
Figure S8 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

CnP effect on NFkB signaling in CAF. GPR68 effect on αSMA in CAF.
Figure S7 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

Bodyweight and serum biochemical tests of mice
Supplementary Table S4 from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Authors: Martin-Broto Javier , Lopez-Alvarez Maria , Moura David S. , Ramos Rafael , Collini Paola , Romagosa Cleofe , Bagué Silvia , Renne Salvatore L. , Barisella Marta , Velasco Valerie , Coindre Jean-Michel , Lopez-Lopez Daniel , Dopazo Joaquin , Gambarotti Marco , Braglia Luca , Merlo Domenico Franco , Palmerini Emanuela , Stacchiotti Silvia , Quagliuolo Vittorio L. , Lopez-Pousa Antonio , Grignani Giovanni , Blay Jean-Yves , Brunello Antonella , Gutierrez Antonio , Valverde Claudia , Hindi Nadia , Dei Tos Angelo Paolo , Picci Piero , Casali Paolo G. , Gronchi Alessandro
Published: April 2023

Supplementary Table S4 - Affinity energies of nilotinib and avapritinib for the different structures of MRP-1.
Figure S6 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

GPR68 expression in HCC cells and CAFs
Figure S5 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

ELISA of CAF-CM and siGPR68 CAF-CM
Figure S2 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

Effect of CAF and CnP on Hep3B
Figure S1 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

(A) Structure of CnP, (B) Negative control of IHC with xenograft tumors
Supplementary Data from Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation
Authors: Wang Weini , Fang Fang , Ozes Ali , Nephew Kenneth P.
Published: April 2023

supplementary data with figure legends
Supplementary Data from International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
Authors: Vassal Gilles , Houghton Peter J. , Pfister Stefan M. , Smith Malcolm A. , Caron Huib N. , Li Xiao-Nan , Shields David J. , Witt Olaf , Molenaar Jan J. , Colombetti Sara , Schüler Julia , Stancato Lou F.
Published: April 2023

Supplementary Data from International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
Supplementary Figure 3 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Authors: Kano Hirohisa , Ichihara Eiki , Watanabe Hiromi , Nishii Kazuya , Ando Chihiro , Nakasuka Takamasa , Ninomiya Kiichiro , Kato Yuka , Kubo Toshio , Rai Kammei , Ohashi Kadoaki , Hotta Katsuyuki , Tabata Masahiro , Maeda Yoshinobu , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 3. Combined use of SHP099 with alectinib, crizotinib or osimertinib Cell viability after treatment with a single agent or a combination of agents relative to the control (set to 1). All drugs were loaded for 96 h. Error bars represent the standard error. *P < 0.01 (one-way ANOVA and the Bonferroni method). S, SHP099; A, alectinib; C, crizotinib; O, osimertinib.
Supplementary Figure 2 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Authors: Kano Hirohisa , Ichihara Eiki , Watanabe Hiromi , Nishii Kazuya , Ando Chihiro , Nakasuka Takamasa , Ninomiya Kiichiro , Kato Yuka , Kubo Toshio , Rai Kammei , Ohashi Kadoaki , Hotta Katsuyuki , Tabata Masahiro , Maeda Yoshinobu , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 2. ROS1 TKI in combination with SHP099 (A) Immunoblots of the indicated proteins in HCC78 and ABC-20 cells treated for 24 h with DS-6051b (Ds, 100 nM) with or without SHP099 (SHP, 5 µM). Comb, combination. (B) RAS-GTP assay in H3122 cells treated with alectinib (Alec, 100 nM), ABC-20 cells treated with crizotinib (Cri, 1 µM) and HCC827 cells treated with osimertinib (Osi, 100 nM) for 24 h. All cell lines were also treated or not with SHP099 (SHP, 5 µM). Comb, combination. (C) Cell viability curves for cell lines treated with DS-6051b (DS) alone (circles), SHP099 (SHP) alone (triangles) or DC6051b and SHP099 (5 µM) (squares). All drugs were loaded for 96 h. Error bars represent the standard error.
Table S1 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

Supplementary Table 1
Figure S7 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

Effect of combinatorial treatment on second PDAC model
Supplementary Data from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
Authors: Cabaud Olivier , Berger Ludovic , Crompot Emerence , Adélaide José , Finetti Pascal , Garnier Sèverine , Guille Arnaud , Carbuccia Nadine , Farina Anne , Agavnian Emilie , Chaffanet Max , Gonçalves Anthony , Charafe-Jauffret Emmanuelle , Mamessier Emilie , Birnbaum Daniel , Bertucci François , Lopez Marc
Published: April 2023

Supplementary Data from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
Figure S6 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

Time line of combinatorial immunotherapy
Supplementary Methods from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
Authors: Wilson Elizabeth A. , Sultana Nahid , Shah Khyati N. , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary methods
Figure S4 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

Effect of IGF-Trap on MDSC activity
Figure S3 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
Authors: Wilson Elizabeth A. , Sultana Nahid , Shah Khyati N. , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Figure 3
Figure S2 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

Reduced IGF-1R activation in IGF-Trap treated immune cells
Supplementary Table from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
Authors: Gopinathan Ganga , Berlato Chiara , Lakhani Anissa , Szabova Ludmila , Pegrum Colin , Pedrosa Ana-Rita , Laforets Florian , Maniati Eleni , Balkwill Frances R.
Published: April 2023

Supplementary Table from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
Table S3 from Anastrozole Regulates Fatty Acid Synthase in Breast Cancer
Authors: Cairns Junmei , Ingle James N. , Kalari Krishna R. , Goetz Matthew P. , Weinshilboum Richard M. , Gao Huanyao , Li Hu , Bari Mehrab Ghanat , Wang Liewei
Published: April 2023

Table S3 shows Overlapped genes (highlighted) between ERα CHIPseq in the presence of anastrozole and RNAseq in the presence of anastrozole.
Supplementary Data from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Authors: Werr Lisa , Plenker Dennis , Dammert Marcel A. , Lorenz Carina , Brägelmann Johannes , Tumbrink Hannah L. , Klein Sebastian , Schmitt Anna , Büttner Reinhard , Persigehl Thorsten , Shokat Kevan M. , Wunderlich F. Thomas , Schram Alison M. , Peifer Martin , Sos Martin L. , Reinhardt H. Christian , Thomas Roman K.
Published: April 2023

Supplementary Data from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Supplementary Information and Figures from Anastrozole Regulates Fatty Acid Synthase in Breast Cancer
Authors: Cairns Junmei , Ingle James N. , Kalari Krishna R. , Goetz Matthew P. , Weinshilboum Richard M. , Gao Huanyao , Li Hu , Bari Mehrab Ghanat , Wang Liewei
Published: April 2023

Supplementary information and Figures S1-S6
Supplementary Data from Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy
Authors: Yi Bin , Cheng Hao , Wyczechowska Dorota , Yu Qingzhao , Li Li , Ochoa Augusto C. , Riker Adam I. , Xi Yaguang
Published: April 2023

Supplementary figures
Supplementary Data from GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling
Authors: Pan Jiajia , Li Nan , Renn Alex , Zhu Hu , Chen Lu , Shen Min , Hall Matthew D. , Qian Min , Pastan Ira , Ho Mitchell
Published: April 2023

Supplementary Data from GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling